Comera Life Sciences Holdings, Inc.
CMRA
$0.0001
$0.000.00%
OTC PK
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | 81.82% | 172.64% | 184.33% | 97.94% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 81.82% | 172.64% | 184.33% | 97.94% | -- |
| Cost of Revenue | 33.18% | 52.39% | 49.10% | 30.68% | -- |
| Gross Profit | 109.31% | 276.01% | 369.86% | 166.08% | -- |
| SG&A Expenses | -27.21% | -7.65% | 72.80% | 129.91% | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -25.04% | -6.58% | 50.21% | 89.63% | -- |
| Operating Income | 30.39% | 14.29% | -44.19% | -89.15% | -- |
| Income Before Tax | 47.21% | 33.35% | -125.78% | -230.24% | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 47.21% | 33.35% | -125.78% | -230.24% | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 47.21% | 33.35% | -125.78% | -230.24% | -- |
| EBIT | 30.39% | 14.29% | -44.19% | -89.15% | -- |
| EBITDA | 30.70% | 14.55% | -44.61% | -90.41% | -- |
| EPS Basic | 96.99% | 97.37% | 92.50% | 69.45% | -- |
| Normalized Basic EPS | 97.65% | 97.85% | 93.07% | 70.12% | -- |
| EPS Diluted | 96.99% | 97.37% | 92.50% | 69.45% | -- |
| Normalized Diluted EPS | 97.65% | 97.85% | 93.07% | 70.12% | -- |
| Average Basic Shares Outstanding | 211.11% | 671.63% | 1,413.99% | 183.46% | -- |
| Average Diluted Shares Outstanding | 211.11% | 671.63% | 1,413.99% | 183.46% | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |